trial · primary record
osimertinib
Non Small Cell Lung Cancer Metastatic
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 56 |
| Primary completion | 2027-12 |
| Primary endpoint | intracranial progression-free survival (iPFS) |
| Registry ID | NCT06741085 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:09.981Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06741085
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Osimertinib · compound